Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

October 08, 2024 at 04:00 AM EDT

~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~

~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~

SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18^th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA.

Dr. Kirkpatrick's presentation "When All You Have is a Hammer ... A New Approach to Soften the Blow" will be held on Monday, October 28th at 1:00 PM Eastern Time.

In this session, Dr. Kirkpatrick will review the proliferation of new analgesic entrants that have promised opioid-like efficacy but to date have not delivered. The result has been opioid mistrust and unfortunately, a reduction in access for those who depend on opioid pain relief for a decent quality of life. Instead of turning away from these effective analgesics, Ensysce embraced their efficacy by introducing new TAAP™ and MPAR® classes of opioids. The lead agents, PF614 and PF614-MPAR, are expected to provide a novel option for high-risk patients delivering exquisite pain relief yet with advantages over currently used Abuse Deterrent Formulation (ADF) opioid products. TAAP-modified opioids reduce multiple forms of abuse and only release the opioid when taken orally and exposed to trypsin in the gut. MPAR applies another layer of safety resulting in oral overdose protection by adding a trypsin inhibitor to each of the TAAP products. Dr. Kirkpatrick will present clinical data demonstrating these unique qualities of TAAP and MPAR and supporting their added benefits over the ADF class.

Ensysce's commitment to the Annual Pain Therapeutics Summit is also represented by Dr. William Schmidt, Chief Medical Officer of Ensysce, who will serve as Chairperson for the second consecutive year. Dr. Schmidt will provide opening remarks on Monday, October 28^th and Tuesday, October 29^th. Dr. Schmidt has specialized in providing advice on preclinical and clinical studies of novel analgesic drugs throughout his career. Dr. Schmidt is the Parliamentarian and a Past President of the Eastern Pain Association. He received the John J. Bonica award for the development of new analgesics and his sustained contributions to the educational efforts of the Eastern Pain Association in 2014.

The Annual Pain Therapeutics Summit is a widely recognized arena for leaders in the fields of advanced medicine and science, academia and government to come together and discuss the latest advances in the quest to develop novel pain therapies. The summit will present thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products. The agenda for this year's event includes a wide variety of topics in the field of pain research, such as the development of novel therapeutics, biomarkers associated with pain states, and clinical trial design considerations. Additionally, the event offers panel discussions on key issues facing pain research today from ethical considerations to funding challenges and beyond. The event is a prominent gathering of experts dedicated to improving the lives of those suffering from chronic pain. Please find more information here.

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from its fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:

Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View the original press release on accesswire.com

About Us

Laser Focus World Membership

Magazine Subscription

Newsletter Subscription

The Daily Beam

Product Watch

Bio & Life Sciences Product Watch

Laser Processing Product Watch

Get Published!

Photonics Hot List

Following the Photons: A Photonics Podcast

Social Media

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit

More News